$The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells$

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells

One of the major obstacles in the treatment of hormone-refractory prostate cancer (HRPC) is the development of chemo-resistant tumors. The aim of this study is to evaluate the role of Palomid 529 (P529), a novel TORC1/TORC2 inhibitor, in association with docetaxel (DTX) and cisplatin (CP). This work...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine-related cancer 2011-08, Vol.18 (4), p.385-400
Hauptverfasser:	Gravina, Giovanni Luca, Marampon, Francesco, Petini, Foteini, Biordi, Leda, Sherris, David, Jannini, Emmanuele A, Tombolini, Vincenzo, Festuccia, Claudio
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis - drug effects Benzopyrans - pharmacology Blotting, Western Cell Cycle - drug effects Cell Line, Tumor Cell Proliferation - drug effects Cisplatin - administration & dosage Drug Resistance, Neoplasm - drug effects Drug Synergism Humans Male Mice Mice, Nude Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - metabolism Neoplasms, Hormone-Dependent - pathology Prostatic Neoplasms - drug therapy Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Proto-Oncogene Proteins c-akt - metabolism PTEN Phosphohydrolase - metabolism Regular papers Taxoids - administration & dosage Transcription Factors - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!